Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significant, clinically relevant activity across Phase...